Assays
Within this product group you will find many: ELISAs, ELISPOTs, protein detection assays, and many more assays.
Experts in providing molecular products and services for oncology testing
Invivoscribe® is a global technology-driven cancer diagnostics company. Our mission is to optimize patient care and accelerate drug approvals worldwide by providing best-in-class products and services.
Invivoscribe provides a comprehensive selection of PCR-based products, including B- & T-cell clonality assays (IGH, IGK, TRG, TRB), chromosome translocations, the LeukoStrat® CDx FLT3 Mutation Assay, NGS gene panels and minimal residual disease (MRD) solutions with bioinformatics software.
Invivoscribe solutions are available as research use only testing reagents and controls as well as CE-marked in vitro diagnostic products.
Improving Lives with Precision Diagnostics®
Bio-Connect supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.
Invivoscribe’s assays inform and guide the patient’s physician from diagnosis through the entire course of therapy.
Ha J, Lee H, Shin S, et al. Ig gene clonality analysis using next-generation sequencing for improved minimal residual disease detection with significant prognostic value in multiple myeloma patients.
Ho C, Syed M, Roshal M, et al. Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high-sensitivity flow cytometry.
Kadkol SS, Bland J, Kavanaugh A, Ni H, Nehru V, Peace D. Ngs analysis of clonality and minimal residual disease in a patient with concurrent richter’s transformation and cll/sll.
Kim M, Jeon K, Hutt K, et al. Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing.
Ho CC, Tung JK, Zehnder JL, Zhang BM. Validation of a next-generation sequencing-based t-cell receptor gamma gene rearrangement diagnostic assay: transitioning from capillary electrophoresis to next-generation sequencing.
Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.
Stamatopoulos B, Timbs A, Bruce D, et al. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
Levis MJ, Perl AE, Altman JK, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.
Arcila ME, Yu W, Syed M, et al. Establishment of immunoglobulin heavy (Igh) chain clonality testing by next-generation sequencing for routine characterization of b-cell and plasma cell neoplasms.
Yao Q, Bai Y, Orfao A, Chim CS. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma.
We gladly support you by keeping you updated on our latest products and the developments around our services.
